Companies are seeking to capitalize on a hot new gene technology, though a high-stakes patent dispute has yet to been settled. The gene-editing tool, known as Crispr-Cas9, serves as a kind of multipurpose molecular scissors that can cut DNA.
Baca Berita Asal
Bagikan Berita Ini
0 Response to "Breakthrough Gene Tech Attracts Investors Amid Patent Dispute"
Post a Comment